drugset / Trial / NCT06663306

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

NCT06663306

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.

Timeline

Start
2024-12-09
Primary completion
2027-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg Intrathecal
Subject Bevacizumab Monoclonal antibody 10 mg Intrathecal
Subject Bevacizumab Monoclonal antibody 25 mg Intrathecal
Subject Bevacizumab Monoclonal antibody 37.5 mg Intrathecal
Subject Bevacizumab Monoclonal antibody 50 mg Intrathecal
Subject Pemetrexed Small molecule 50 mg Intrathecal